Business
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
QUEENSBURY, N.Y., February 12, 2026--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025.
About this update from Delcath Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f0e11276219f94d3ea97d4352250fe48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X6jMRwLJqgACYAGTK5jx4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f0e11276219f94d3ea97d4352250fe48","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rRuDm5wPfoUZM9YSMaMt7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f0e11276219f94d3ea97d4352250fe48","width":1024,"height":512}},"lazy":false},{"type":"text","content":"QUEENSBURY, N.Y., February 12, 2026--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025.","length":373,"tagName":"p"},{"type":"text","content":"Conference Call Information","length":27,"tagName":"p"},{"type":"text","content":"To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.","length":101,"tagName":"p"},{"type":"text","content":"Event Date: Thursday, February 26, 2026Time: 8:30 AM Eastern Time","length":66,"tagName":"p"},{"type":"text","content":"Participant Numbers:Toll Free: 1-877-407-3982International: 1-201-493-6780Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.","length":300,"tagName":"p"},{"type":"text","content":"About Delcath Systems, Inc., HEPZATO KIT and CHEMOSATDelcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and a...